Technical Analysis for DERM - Dermira, Inc.

Grade Last Price % Change Price Change
grade D 9.71 -4.15% -0.42
DERM closed down 4.15 percent on Friday, November 16, 2018, on 1.25 times normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Down
See historical DERM trend table...

Date Alert Name Type % Chg
Nov 16 Slingshot Bearish Bearish Swing Setup 0.00%
Nov 16 Spinning Top Other 0.00%
Nov 16 Lower Bollinger Band Walk Weakness 0.00%
Nov 16 Multiple of Ten Bearish Other 0.00%
Nov 16 Outside Day Range Expansion 0.00%
Nov 16 Wide Bands Range Expansion 0.00%
Nov 16 Lower Bollinger Band Touch Weakness 0.00%
Nov 16 Oversold Stochastic Weakness 0.00%
Nov 15 Stochastic Buy Signal Bullish -4.15%
Nov 15 Lower Bollinger Band Walk Weakness -4.15%

Older signals for DERM ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Dermira, Inc., a specialty biopharmaceutical company, focuses on the development and commercialization of medical dermatology products to dermatologists and their patients primarily in the United States. The company's late-stage product candidates comprise Cimzia, an injectable biologic tumor necrosis factor-alpha inhibitor, which has completed Phase II clinical trials for the treatment of moderate-to-severe plaque psoriasis; DRM04, a anticholinergic product that is in a Phase IIb clinical trial for the treatment of hyperhidrosis or excessive sweating; and DRM01, a sebum inhibitor, which has completed a Phase IIa clinical trial for the treatment of acne. Its early-stage programs in preclinical development include DRM02, an inhibitor of phosphodiesterase-4 for the treatment of inflammatory skin diseases; and DRM05, a photodynamic therapy for the treatment of acne. Dermira, Inc. has a collaboration agreement with UCB Pharma S.A. for the development and commercialization of Cimzia. The company was formerly known as Skintelligence, Inc. and changed its name to Dermira, Inc. in September 2011. Dermira, Inc. was founded in 2010 and is headquartered in Redwood City, California.
Is DERM a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 31.42
52 Week Low 6.98
Average Volume 553,981
200-Day Moving Average 11.6391
50-Day Moving Average 11.4456
20-Day Moving Average 11.598
10-Day Moving Average 10.927
Average True Range 0.9036
ADX 23.81
+DI 12.3283
-DI 26.5952
Chandelier Exit (Long, 3 ATRs ) 11.1292
Chandelier Exit (Short, 3 ATRs ) 11.9208
Upper Bollinger Band 13.6725
Lower Bollinger Band 9.5235
Percent B (%b) 0.04
BandWidth 35.773409
MACD Line -0.4583
MACD Signal Line -0.1388
MACD Histogram -0.3195
Fundamentals Value
Market Cap 405.53 Million
Num Shares 41.8 Million
EPS -2.70
Price-to-Earnings (P/E) Ratio -3.60
Price-to-Sales 43.67
Price-to-Book 2.90
PEG Ratio -0.05
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 11.68
Resistance 3 (R3) 11.73 11.12 11.35
Resistance 2 (R2) 11.12 10.62 11.10 11.24
Resistance 1 (R1) 10.42 10.31 10.12 10.37 11.13
Pivot Point 9.81 9.81 9.66 9.79 9.81
Support 1 (S1) 9.11 9.31 8.81 9.06 8.29
Support 2 (S2) 8.50 9.00 8.48 8.18
Support 3 (S3) 7.80 8.50 8.07
Support 4 (S4) 7.75